Published 5 days ago • loading... • Updated 5 days ago

Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

On Monday, Innovent Biologics showcased clinical and preclinical data for bispecific antibodies at the American Thoracic Society International Conference in Orlando and the Association for Research in Vision and Ophthalmology Annual Meeting in Denver.
The company highlighted IBI3002, a first-in-class anti-IL-4Rα/TSLP bispecific antibody for asthma, alongside preclinical candidates IBI3038 and IBI3031 designed to target autoimmune and ophthalmological disease mechanisms.
In a Phase 1b study, IBI3002 showed favorable tolerability and improved pulmonary function, with treatment achieving greater pre-bronchodilator forced expiratory volume in one second of 0.18L versus 0.15L for placebo.
Innovent plans to advance IBI3002 development for asthma and atopic dermatitis, while IBI3038 and IBI3031 are scheduled to enter clinical stages in 2026.
Dr. Huizhong Xiong, Vice President of Innovent Academy , stated these programs "further validate our R&D capabilities in bispecific platforms and mechanism innovation.

Insights by Ground AI

22 Articles

Helena Independent Record

+21 Reposted by 21 other sources

Center

Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

SAN FRANCISCO and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other…

5 days ago·Helena, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year